Good
Mostly Aligned
Patient Risk:
Low
Summary
Most safety-related claims (infection risk, avoid live vaccines, prompt clinician contact for serious infection) are supported by the provided labeling excerpts. However, the elderly/age-specific assertions are only partially addressable from the supplied label text: the label discusses geriatric use generally but does not explicitly state the absence of an elderly-only restriction or that safety considerations apply regardless of age in the exact way claimed.
Category Scores
Accurate Statements
Cosentyx can increase the risk of infections.
5.1 Infections: “COSENTYX may increase the risk of infections.”
Live vaccines should be avoided during Cosentyx treatment.
5.7 Immunizations: “Avoid use of live vaccines in patients treated with COSENTYX.”; 17 Patient Counseling: “Vaccination with live vaccines is not recommended during COSENTYX treatment.”
Patients are advised to avoid certain live vaccines during Cosentyx treatment.
5.7 Immunizations: “Avoid use of live vaccines in patients treated with COSENTYX.”
If an elderly patient develops signs of infection, they should contact their clinician promptly.
5.1 Infections: “If a patient develops a serious infection… discontinue COSENTYX until the infection resolves.” and 17 Patient Counseling: “COSENTYX may lower the ability of their immune system to fight infections and that serious infections… may occur…” (together supporting the need for patient action/medical attention for serious infection).
Unsupported Statements
Cosentyx (secukinumab) does not have an “elderly-only” restriction or an age cutoff described in the provided information.
The provided excerpts include geriatric use language (8.5) and pediatric age limitations, but do not explicitly address whether an “elderly-only” restriction or an age cutoff exists; absence of that specific restriction cannot be confirmed from the supplied text.
Cosentyx is used in adults across a range of ages, including older patients, using the same labeled dosing regimen.
8.5 states no observed differences in safety/efficacy between ≥65 and younger adults, but the provided excerpts do not explicitly state that the same labeled dosing regimen is used across ages/that dosing is unchanged for geriatric patients.
The provided information does not specify different dosing for elderly patients.
While 8.5 does not describe dose changes, the supplied dosage section excerpts also do not explicitly list geriatric dosing instructions; from the provided text, this can’t be fully confirmed as an explicit “no different dosing” statement.
The provided information states safety considerations apply regardless of age, including infection risk.
The infection risk warning (5.1) is not stated as age-independent in the provided excerpts, and 8.5 is about observed differences and sample size, not an explicit statement that safety considerations apply regardless of age.
Contradictions
Important Omissions
No mention of TB screening/evaluation and monitoring prior to and during therapy for infection risk (5.3).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The key safety statements made (infection risk and avoiding live vaccines) align with the provided label excerpts. The main gaps are overconfident age-related assertions that are not explicitly stated in the supplied labeling text.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Age/elderly restriction and age-independent safety applicability were stated more strongly than the provided label excerpts explicitly support.
Suggested Improvement
Rephrase age-related claims to align with the supplied label: cite 8.5 geriatric use language about no observed safety/efficacy differences (with insufficient numbers to determine differences), and avoid asserting absence of an “elderly-only” restriction or that safety considerations explicitly apply regardless of age unless directly stated.